Tonix Pharmaceuticals Holding Corp.(TNXP)Stock Analysis

TNXP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tonix Pharmaceuticals Holding Corp. (TNXP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNXP at 27.9/100 on a 32-signal composite quality model, placing it at rank #2,458 of 2,879 stocks — the bottom half of the AI-ranked universe. TNXP scores in the top quartile across revenue growth (98.1), institutional flow (85.5). Areas of concern include profitability (2.7) and free cash flow (2.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Tonix Pharmaceuticals Holding Corp. reports quarterly revenue of $6.9M, net income of $-40.2M, free cash flow of $-44.0M. Top institutional holders of TNXP by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. TNXP trades on the Nasdaq exchange and files with the SEC under CIK 1430306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tonix Pharmaceuticals Holding Corp. directly from SEC EDGAR. Tonix Pharmaceuticals Holding Corp.'s 13F Pro composite quality score has ranged between 9 and 28 since 2025, currently 27.9 — an improving long-term trajectory across 11 quarterly and live scoring snapshots.